DCXR divergent transcript (DCXR-DT)

DCXR divergent transcript (DCXR-DT; RP13-650J16.1) is a gene that encodes a long non-coding RNA, not a typical drug target such as a receptor or enzyme[7]. It is located adjacent to the DCXR gene but does not encode a protein itself. Studies have shown that RP13-650J16.1 is upregulated in prostate cancer tissue, where it acts as an oncogene, promoting cell proliferation, migration, and colony formation in vitro. Knockdown of this lncRNA reduces the expression of its neighboring gene RAC3 and inhibits tumor-like properties in prostate cancer DU145 cells[2][4]. There are currently no known drugs that interact directly with this non-coding RNA, and it is not recognized as a therapeutic target per se[7]. Key Points: - DCXR-DT is a long non-coding RNA, not a receptor, enzyme, or typical therapeutic target[7]. - Aliases include the clone or transcript IDs commonly used in non-coding RNA annotation. - Its main research association is with prostate cancer, where it may regulate oncogenic processes[2][4]. - There is no evidence of direct druggability or a current role as a clinical biomarker; no interacting drugs or safety concerns have been described[2][4][7]. - The entry is not incorrect or misspelled, but this is not a standard therapeutic target. If you seek information about the protein-coding gene DCXR (Dicarbonyl and L-xylulose reductase), which is distinct and has well-characterized enzymatic functions, please clarify.

Other names

RP13-650J16.1DCXR-DT